Kyoto University’s CiRA has initiated a service based on human leukocyte-antigen (HLA)-typed iPS cell stocks. Appropriate HLA-types in tissue transplantation greatly reduces the risk of rejection. This time, CiRA has offered to Dainippon Sumitomo and its Helios joint venture to prepare HLA-typed retinal pigment epithelial cells (RPE cells) for clinical trials with appropriate patients, to be started in 2017.

CiRA website, Nikkei Biotech news release August 6, 2015